Cargando…

Coexisting Germline CHEK2 and Somatic BRAF(V600E) Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course

BRAF(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC) and the majority of evidence indicates that it is associated with an aggressive clinical course. Germline mutations of the CHEK2 gene impair the DNA damage repair process and increase the risk of PTC. Coexistence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gąsior-Perczak, Danuta, Kowalik, Artur, Walczyk, Agnieszka, Siołek, Monika, Gruszczyński, Krzysztof, Pałyga, Iwona, Mikina, Estera, Trybek, Tomasz, Kopczyński, Janusz, Mężyk, Ryszard, Góźdź, Stanisław, Kowalska, Aldona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896084/ https://www.ncbi.nlm.nih.gov/pubmed/31703344 http://dx.doi.org/10.3390/cancers11111744

Ejemplares similares

Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2021)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population
por: Kowalik, Artur, et al.
Publicado: (2017)

Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications
por: Kowalik, Artur, et al.
Publicado: (2017)

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
por: Kowalska, Aldona, et al.
Publicado: (2015)

The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2018)

The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence
por: Kowalska, Aldona, et al.
Publicado: (2016)

Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients
por: Walczyk, Agnieszka, et al.
Publicado: (2020)

Does the TT Variant of the rs966423 Polymorphism in DIRC3 Affect the Stage and Clinical Course of Papillary Thyroid Cancer?
por: Hińcza, Kinga, et al.
Publicado: (2020)

Diagnostic performance evaluation of post-operative serum calcitonin (CT) levels as a factor for good prognosis in medullary thyroid carcinoma (MTC)
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2013)

Delayed risk stratification system in pT1aN0/Nx DTC patients treated without radioactive iodine
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2017)

Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy
por: Hińcza-Nowak, Kinga, et al.
Publicado: (2021)

CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer
por: Hińcza-Nowak, Kinga, et al.
Publicado: (2023)

Variation of the epidemiological structure of thyroid cancer between year 2000 and 2012
por: Kowalska, Aldona, et al.
Publicado: (2013)

Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?
por: Gajowiec, Aleksandra, et al.
Publicado: (2021)

Papillary Thyroid Cancer in a Struma Ovarii in a 17-Year-Old Nulliparous Patient: A Case Report
por: Gonet, Agnieszka, et al.
Publicado: (2020)

Telomeres and telomerase in oncogenesis
por: Trybek, Tomasz, et al.
Publicado: (2020)

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAF(V600E) Positive Papillary Thyroid Carcinoma
por: Wieczorek-Szukala, Katarzyna, et al.
Publicado: (2020)

Are molecular tests necessary to diagnose NIFTP?
por: Kuchareczko, Artur, et al.
Publicado: (2021)

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity
por: Zajkowska, Klaudia, et al.
Publicado: (2020)

Effective Preoperative Plasmapheresis Treatment of Severe Hyperthyroidism in a Patient with Giant Toxic Nodular Goiter and Methimazole-Induced Agranulocytosis
por: Barwinek, Katarzyna, et al.
Publicado: (2020)

Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease
por: Lewandowski, Krzysztof C, et al.
Publicado: (2012)

Evaluation of ultrasound-guided fine needle aspiration biopsy (USG-FNAB) of thyroid nodules: 12 years of accepted diagnostic algorithm in Holycross Cancer Centre (HCC) in Kielce
por: Sygut, Jacek, et al.
Publicado: (2013)

Effectiveness analysis of papillary thyroid carcinoma (PTC) diagnostics in Holycross Cancer Centre (HCC) in Kielce according to fine needle aspiration biopsy quality assurance program in pathology department between years 2001 and 2012
por: Sygut, Jacek, et al.
Publicado: (2013)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study
por: Kowalik, Artur, et al.
Publicado: (2018)

Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation
por: Walczyk, Agnieszka, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
por: Larkin, Sarah Jane, et al.
Publicado: (2014)

Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility
por: Przybycień, Piotr, et al.
Publicado: (2022)

Repeated nondiagnostic result of thyroid fine-needle aspiration biopsy
por: Ziemiańska, Klaudia, et al.
Publicado: (2017)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
por: Yu, Huan, et al.
Publicado: (2017)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ukbmhp6mirqkl5h8nsj8ss8t4j